Pilot study of a novel short-cycle antiretroviral treatment interruption strategy: 48-week results of the five-days-on, two-days-off (FOTO) study

被引:70
作者
Cohen, Calvin J.
Colson, Amy E.
Sheble-Hall, Alexander G.
McLaughlin, Karen A.
Morse, Gene D.
机构
[1] Community Res Initiat New England, Boston, MA 02215 USA
[2] Harvard Univ, Sch Med, Boston, MA USA
[3] Harvard Vanguard Med Assoc, Boston, MA USA
[4] Cambridge Hlth Alliance, Cambridge, MA USA
[5] SUNY Buffalo, Amherst, NY USA
来源
HIV CLINICAL TRIALS | 2007年 / 8卷 / 01期
关键词
antiretroviral therapy; efavirenz; structured treatment interruption;
D O I
10.1310/hct0801-19
中图分类号
R51 [传染病];
学科分类号
100401 ;
摘要
Purpose: The challenges associated with daily lifelong antiretroviral therapy (ART) have stimulated interest in alternative treatment schedules, including planned, cyclical interruptions of therapy in patients with virologic suppression and sufficient CD4(+) T-cell counts. Method: We conducted a 48-week, open-label, single-arm, prospective pilot study of a novel short-cycle treatment interruption strategy. Upon enrollment, 30 HIV+ individuals with a history of durable viral suppression on daily ART changed their weekly treatment schedule to 5 consecutive days on treatment (typically Monday through Friday) followed by 2 days off treatment (five-on, two-off, or FOTO treatment schedule). Results: At 24 and 48 weeks, as-treated analysis revealed that virologic suppression was maintained in 26/29 subjects (89.6%), including 100% of subjects taking efavirenz-based regimens. Participants adhered well to the FOTO treatment schedule and expressed a strong preference for the FOTO treatment schedule compared to daily ART Conclusion: If validated, the FOTO treatment strategy with efavirenz-based regimens could avoid the viremia witnessed in longer cycle structured treatment interruptions yet still ameliorate a number of problems associated with the current paradigm of daily ART for HIV infection, including the high cost of therapy and the pill fatigue that, in many patients, leads to erratic adherence and ultimately treatment failure.
引用
收藏
页码:19 / 23
页数:5
相关论文
共 11 条
[1]   Position paper on therapeutic drug monitoring of antiretroviral agents [J].
Acosta, EP ;
Gerber, JG .
AIDS RESEARCH AND HUMAN RETROVIRUSES, 2002, 18 (12) :825-834
[2]   Failures of 1 week on, 1 week off antiretroviral therapies in a randomized trial [J].
Ananworanich, J ;
Nuesch, R ;
Le Braz, M ;
Chetchotisakd, P ;
Vibhagool, A ;
Wicharuk, S ;
Ruxrungtham, K ;
Furrer, H ;
Cooper, D ;
Hirschel, B .
AIDS, 2003, 17 (15) :F33-F37
[3]   Less than 95% adherence to nonnucleoside reverse-transcriptase inhibitor therapy can lead to viral suppression [J].
Bangsberg, David R. .
CLINICAL INFECTIOUS DISEASES, 2006, 43 (07) :939-941
[4]   Long-cycle structured intermittent versus continuous highly active antiretroviral therapy for the treatment of chronic infection with human immunodeficiency virus: Effects on drug toxicity and on immunologic and virologic parameters [J].
Dybul, M ;
Nies-Kraske, E ;
Daucher, M ;
Hertogs, K ;
Hallahan, CW ;
Csako, G ;
Yoder, C ;
Ehler, L ;
Sklar, PA ;
Belson, M ;
Hidalgo, B ;
Metcalf, JA ;
Davey, RT ;
Kress, DMR ;
Powers, A ;
Fauci, AS .
JOURNAL OF INFECTIOUS DISEASES, 2003, 188 (03) :388-396
[5]  
El-Sadr WM, 2006, NEW ENGL J MED, V355, P2283, DOI 10.1056/NEJMoa062360
[6]   Medical progress - Cardiovascular risk and body-fat abnormalities in HIV-infected adults. [J].
Grinspoon, S ;
Carr, A .
NEW ENGLAND JOURNAL OF MEDICINE, 2005, 352 (01) :48-62
[7]   Quality assurance program for pharmacokinetic assay of antiretrovirals: ACTG proficiency testing for pediatric and adult pharmacology support laboratories, 2003 to 2004 - A requirement for therapeutic drug monitoring [J].
Holland, Diane T. ;
DiFrancesco, Robin ;
Connor, James D. ;
Morse, Gene D. .
THERAPEUTIC DRUG MONITORING, 2006, 28 (03) :367-374
[8]   Quality assurance program for clinical measurement of antiretrovirals: AIDS Clinical Trials Group proficiency testing program for pediatric and adult pharmacology laboratories [J].
Holland, DT ;
DiFrancesco, R ;
Stone, J ;
Hamzeh, F ;
Connor, JD ;
Morse, GD .
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 2004, 48 (03) :824-831
[9]   Reverse phase high-performance liquid chromatography method for the analysis of amprenavir, efavirenz, indinavir, lopinavir, nelfinavir and its active metabolite (M8), ritonavir, and saquinavir in heparinized human plasma [J].
Keil, K ;
Frerichs, VA ;
DiFrancesco, R ;
Morse, G .
THERAPEUTIC DRUG MONITORING, 2003, 25 (03) :340-346
[10]   Adherence to protease inhibitor therapy and outcomes in patients with HIV infection [J].
Paterson, DL ;
Swindells, S ;
Mohr, J ;
Brester, M ;
Vergis, EN ;
Squier, C ;
Wagener, MM ;
Singh, N .
ANNALS OF INTERNAL MEDICINE, 2000, 133 (01) :21-30